IP Library Granted Patent US 12678467
Granted Patent B2
US 12678467 · App. 19/267,709 · Granted Jul 14, 2026

Mixed Bifidobacterium strain with excellent productivity and anti-inflammatory activity, and uses thereof

Inventors: Ye Ji You (Siheung-si, KR); Je Seong Park (Seoul, KR); Gi Deok Park (Jinju-si, KR); Minn Sohn (Jinju-si, KR)
Assignee: LACTOMASON CO., LTD.
A61K35/745A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678467
App. No.
19/267,709
Granted
Jul 14, 2026
Kind
B2
Abstract

Provided is a mixed strain with both excellent anti-inflammatory activity and excellent productivity, including Bifidobacterium animalis subsp. lactis LM1017 (Accession No. KCCM12629P), Bifidobacterium breve LM1092 (Accession No. KCCM13464P), Bifidobacterium longum LM1024 (Accession No. KCCM12919P), and Bifidobacterium bifidum LM1108 (Accession No. KCCM13463P). The strain provided herein has an excellent commercial viability of probiotics.

Claims (14)

1 . A mixed strain with both excellent anti-inflammatory activity and excellent productivity, comprising:

Bifidobacterium animalis subsp. lactis LM1017 deposited with the Korean Culture Center of Microorganisms under Accession No. KCCM12629P;

Bifidobacterium breve LM1092 deposited with the Korean Culture Center of Microorganisms under Accession No. KCCM13464P;

Bifidobacterium longum LM1024 deposited with the Korean Culture Center of Microorganisms under Accession No. KCCM12919P; and

Bifidobacterium bifidum LM1108 deposited with the Korean Culture Center of Microorganisms under Accession No. KCCM13463P,

wherein a mixing ratio of the mixed strain is 32:1 to 1:32 based on “LM1017 and LM1092”:“LM1024 and LM1108”.

2 . The mixed strain of claim 1 ,

wherein the anti-inflammatory activity includes the inhibition of nitric oxide production.

3 . An anti-inflammatory composition containing the mixed strain of claim 1 , a culture thereof, a lysate thereof, an extract thereof, or a combination thereof as an active ingredient.

4 . An anti-inflammatory food composition containing the mixed strain of claim 1 , a culture thereof, a lysate thereof, and an extract thereof, or a combination thereof as an active ingredient.

5 . An anti-inflammatory health functional food composition containing the mixed strain of claim 1 , a culture thereof, a lysate thereof, an extract thereof, or a combination thereof as an active ingredient.

6 . An anti-inflammatory pharmaceutical composition containing the mixed strain of claim 1 , a culture thereof, a lysate thereof, an extract thereof, or a combination thereof as an active ingredient.

7 . A method of improving anti-inflammatory activity, comprising:

a process of administering to a subject in need thereof the mixed strain of claim 1 , a culture thereof, a lysate thereof, an extract thereof, or a combination thereof.